About this trial
The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention.
Participants will:
* consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg) * complete 3 separate 24 hour study cycles * submit blood and urine samples for 24 hours * follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)
Eligibility criteria
Qualifiers
Healthy adults, 18-60 years of age
Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle
Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle
Must be able to give written informed consent
Disqualifiers
Body Mass Index (BMI) <18.5 or >30.0 kg/m2
Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
Pregnancy, breastfeeding, or planning to become pregnant before completing the study
Engaging in vigorous exercise more than 7 hours per week
Trial design
Treatments tested in this trial
- Avmacol Extra Strength with coating - 1 tablet
- Avmacol chewable wafer - 2 tablets
- Avmacol Extra Strength with coating - 2 tablets